A 29-year-old cisgender woman recently diagnosed with HIV presents to clinic for follow-up. Her baseline laboratory studies showed a CD4 count of 257 cells/mm3 and an HIV RNA level of 42,690 copies/mL. She initially took bictegravir-tenofovir alafenamide-emtricitabine for about 10 days but did not tolerate it due to sleep problems and is not willing to take any other similar regimen. She is asking to receive a single tablet regimen. She is HLA-B*5701 positive. You discuss possible single-tablet regimen options and are planning to use a regimen with a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the anchor drug. Which one of the following is TRUE about the following single-tablet non-nucleoside reverse transcriptase inhibitor (NNRTI)-based options? Doravirine-tenofovir DF-lamivudine can be taken with or without food Rilpivirine-tenofovir DF-emtricitabine can be taken with or without food Rilpivirine-tenofovir alafenamide-emtricitabine can be taken with or without food A proton pump inhibitor (PPI) cannot be given to patients who are taking doravirine-tenofovir DF-lamivudine
